OpenBioGen-AI
Bioinformatics Clinical Decision Platform with Gene-Disease Association Mapping
The Enterprise Problem & Core Constraints
Academic molecular biologists and clinical pharmacologists lack accessible, free-tier computational platforms to cross-examine gene targets, evaluate drug binding affinities, and predict disease phenotypes without expensive proprietary software licenses.
AxonFlow AI engineered OpenBioGen-AI: an open-source clinical bioinformatics platform. By unifying data streams from ChEMBL, UniProt, and Open Targets into an interactive analytical UI, OpenBioGen enables researchers to screen drug candidates and visualize molecular properties in seconds.
Quantified Business ROI
Empowered researchers across 12 academic institutions with free, reproducible drug discovery pipelines, accelerating target validation workflows for rare genetic conditions.
Multi-Tier Production Architecture
Federated Biomedical Query
Dispatches asynchronous queries across NCBI Entrez, ChEMBL, and UniProt REST endpoints with automated rate-limiting.
Target-Disease Association
Computes statistical association scores linking human target genes to complex genetic diseases and clinical phenotypes.
Chemical Property Calculator
Calculates Lipinski's Rule of Five parameters (molecular weight, LogP, H-bond donors/acceptors) to assess drug-likeness.
Interactive Scientific Plots
Generates publication-ready interactive Plotly charts, heatmaps, and phylogenetic tree distributions ready for export.
Enterprise Technical Specifications
Live Production Application Preview
Need a Custom System Built with This Architecture?
AxonFlow AI takes enterprise software from initial architectural scoping to live production deployment with guaranteed uptime SLAs and complete code ownership.